At Alfa Cytology, we recognize that the future of cancer therapy lies in combining cutting-edge technologies to achieve superior outcomes. Our oncolytic bacteria-based synergistic combination therapy platform leverages the unique properties of oncolytic bacteria to enhance the efficacy of existing therapies, creating a powerful synergy that targets cancer from multiple angles. Under the leadership of OncoBact™, we are at the forefront of advancing innovative cancer therapies through cutting-edge oncolytic bacteria technology. Whether you are developing breakthrough monotherapies or exploring the transformative potential of synergistic combination therapies, our OncoBact™ platform and one-stop oncolytic bacterial therapy development platform offers comprehensive solutions tailored to accelerate your journey from discovery to clinical success.
Oncolytic bacteria therapy represents an innovative approach in cancer treatment, leveraging engineered oncolytic bacteria to selectively infect and destroy cancer cells while simultaneously activating the patient's immune system. By releasing tumor antigens, this therapy achieves precision targeting of tumors, directly killing cancer cells while reshaping the tumor microenvironment. This dual mechanism not only enhances the immune system's ability to recognize and attack cancer cells but also provides a novel solution for cancer therapy. As cancer treatment evolves into an era of precision medicine and immunotherapy, the limitations of single-agent therapies have become increasingly apparent. Synergistic combination therapy, which integrates oncolytic bacteria with cutting-edge treatments such as immune checkpoint inhibitors, CAR-T cell therapy, and radiation therapy, maximizes therapeutic efficacy while minimizing side effects. This approach addresses complex cancer challenges by leveraging the unique properties of oncolytic bacteria to amplify the effects of complementary therapies.
Fig. 1 An overview of bacteria-based synergistic therapy, namely, the mechanism of tumor targeting properties, combined therapy with chemoradiotherapy or immunotherapy, chemical modification or biological engineering, and bacteria-mediated delivery of cancer vaccine. (Bao, Y., et al., 2022)
Oncolytic bacteria therapy is redefining the future of cancer treatment by harnessing the power of engineered bacteria to selectively target and destroy cancer cells. The introduction of synergistic combination therapy further amplifies the therapeutic potential of oncolytic bacteria, providing a powerful tool to address complex cancer challenges.
Multi-Dimensional Attack
Oncolytic bacteria work synergistically with other therapies to attack tumors from multiple angles, including direct tumor lysis, immune activation, and microenvironment remodeling. This multi-pronged strategy enhances overall therapeutic outcomes.
Personalized Treatment
By combining therapies flexibly, our platform enables tailored treatment strategies that align with the specific characteristics of a patient's tumor, ensuring optimal therapeutic outcomes.
Developmental Potential
Preclinical studies and early-phase clinical trials have demonstrated significant improvements in therapeutic efficacy with synergistic combination therapies, offering new hope for the treatment of complex cancers.
Choose oncolytic bacteria-based synergistic combination therapy platform and unlock the transformative potential of your cancer therapy innovations. Our platform is designed to streamline the development of cutting-edge combination therapies, integrating the power of oncolytic bacteria with other treatments. At Alfa Cytology, our team of experts ensures precision targeting, enhanced safety, and maximized therapeutic efficacy, all while adhering to industry-leading standards.
Combination with Checkpoint Inhibitors
Oncolytic bacteria enhance the efficacy of checkpoint inhibitors by increasing tumor antigen presentation and local immune activation, overcoming resistance mechanisms.
Combination with Bispecific Antibodies
By pairing oncolytic bacteria with bispecific antibodies, our platform enables precise targeting of tumor cells while simultaneously activating T cells, enhancing the immune response against cancer.
Combination with CAR-T Cells
Alfa Cytology enables oncolytic bacteria to deliver cytokines or co-stimulatory molecules directly to the tumor microenvironment, boosting CAR-T cell persistence and function.
Combination with Radiation Therapy
Radiation-induced DNA damage sensitizes cancer cells to oncolytic bacteria, while bacteria mitigate radiation-induced fibrosis and enhance immune infiltration.
By leveraging our platform, you gain access to flexible, scalable, and scientifically validated services, accelerating your journey from concept to clinical success. Partner with Alfa Cytology to harness the full potential of synergistic combination therapies and redefine the future of cancer treatment. For more on our solution, please contact us.
Reference
For research use only.
Alfa Cytology is a leading oncolytic bacteria technology platform provider, specializing in precision-targeted bacterial therapy development and end-to-end solution delivery.
Copyright © 2025 Alfa Cytology. All rights reserved.